rs12936231 — ORMDL3 ORMDL3 17q21 eQTL

ORMDL3 17q21 — The Asthma Gateway Variant

The chromosome 17q21 locus is the most robustly replicated genetic risk region for childhood-onset asthma, identified in the landmark Moffatt et al. 2007 GWAS¹¹ Moffatt et al. 2007 GWAS
994 asthma cases vs 1,243 controls; 17q21 SNPs reached p<10⁻¹²; ORMDL3 expression was the strongest correlate across all genes at the locus in Nature. Among the constellation of correlated variants in this locus, rs12936231 stands out as the most powerful eQTL²² eQTL
expression quantitative trait locus — a variant that changes how much of a nearby gene is produced, rather than changing the protein itself for ORMDL3 in circulating blood cells. It sits within an intron of ZPBP2, in the heart of a ~130-kb regulatory haploblock spanning IKZF3, ZPBP2, GSDMB, ORMDL3, LRRC3C, and GSDMA.

ORMDL3 encodes an endoplasmic reticulum transmembrane protein that is a master regulator of sphingolipid synthesis³³ sphingolipid synthesis
ORMDL3 inhibits serine palmitoyltransferase, the rate-limiting enzyme in de novo ceramide/sphingolipid biosynthesis, linking ER homeostasis to airway inflammation. When ORMDL3 is overexpressed, ER stress accumulates, NF-κB and STAT3 pathways activate, and airway epithelial cells release pro-inflammatory cytokines that drive asthma exacerbations and allergic wheeze.

The Mechanism

rs12936231 lies within a critical regulatory hub. The C and G alleles differ in how they position nucleosomes and recruit CTCF⁴⁴ CTCF
CTCF is a chromatin insulator protein that controls 3D genome folding; its binding site preferences can switch at SNP positions, reshaping which enhancers talk to which promoters. The asthma-risk (C) allele and the nearby rs4065275 together switch the CTCF occupancy pattern at the ZPBP2 region, creating distinct long-range promoter-enhancer loops that are absent in G-allele carriers. The functional consequence: CD4+ T cells from risk-allele carriers show approximately 3-fold higher ORMDL3 expression⁵⁵ approximately 3-fold higher ORMDL3 expression
Schmiedel et al. 2016 — ORMDL3 mRNA levels were ~3-fold elevated in activated CD4+ T cells from risk haplotype carriers vs. non-risk carriers.

Elevated ORMDL3 inversely suppresses IL-2 production in activated memory T cells: when ORMDL3 was knocked down experimentally, IL-2 increased significantly, demonstrating that the risk haplotype dampens one arm of adaptive immunity (IL-2-driven T cell expansion) while amplifying innate airway inflammation.

The most precise quantification of rs12936231's regulatory role came from an eQTL fine-mapping study in African American children⁶⁶ eQTL fine-mapping study in African American children
Ober et al. 2020 Lancet Resp Med, n=85 PBMC donors; rs12936231 showed β=1.19 [1.12-1.24] for ORMDL3 and β=1.24 [1.15-1.32] for GSDMB, p<0.0001 for both, confirming it as the top eQTL across the locus in blood cells.

The Evidence

The connection between rs12936231 genotype and childhood asthma risk is multi-layered. The strongest clinical evidence comes from the vitamin D × 17q21 interaction studies⁷⁷ vitamin D × 17q21 interaction studies
Kelly et al. ERJ 2019 (VDAART cohort) and Knihtilä et al. ERJ 2021 (VDAART + COPSAC2010): GG children whose mothers received prenatal vitamin D3 had 51% lower asthma/wheeze risk (HR 0.49, p=0.032); CC children showed no benefit (HR 1.08, p=0.751), which established a pharmacogenomic interaction: vitamin D3 supplementation works partly by upregulating sphingolipid synthesis enzymes that ORMDL3 normally suppresses. In CC individuals, constitutively elevated ORMDL3 blocks this pathway, abolishing the protective effect.

A 2021 maternal cohort study replicated this finding across two independent trials (VDAART HR 0.54, p<0.001; COPSAC2010 HR 0.56, p=0.021⁸⁸ VDAART HR 0.54, p<0.001; COPSAC2010 HR 0.56, p=0.021
Knihtilä et al. ERJ 2021 — maternal GG/GC genotype predicted offspring vitamin D response in both North American and Danish cohorts), identifying the maternal genotype — not just the child's — as the key modulator.

Allele-specific chromatin remodeling at ZPBP2/GSDMB/ORMDL3⁹⁹ Allele-specific chromatin remodeling at ZPBP2/GSDMB/ORMDL3
Verlaan et al. AJHG 2009 — allele-specific nucleosome positioning and promoter activity identified at rs12936231; haplotype association p=1.78×10⁻⁸ established the functional basis for why rs12936231 has independent regulatory significance beyond simply being in LD with other 17q21 SNPs.

Practical Actions

The clinical implication for C-allele carriers centers on airway inflammation management and the vitamin D–sphingolipid axis. Because elevated ORMDL3 blunts the anti-inflammatory effects of vitamin D on airway epithelium, CC individuals require higher circulating 25(OH)D levels to achieve the same sphingolipid-normalization effect that GG individuals get at standard supplementation levels. Maintaining 25(OH)D above 40–50 ng/mL (100–125 nmol/L) — rather than the standard "sufficient" threshold of 20 ng/mL — is supported by the mechanistic data in this pathway.

The interaction with smoking documented in UK adults suggests the C-allele effect on airway inflammation is amplified by tobacco smoke exposure, making avoidance of smoke exposure particularly important for C-allele carriers with asthma or allergic airway disease.

Interactions

rs12936231 is in strong but incomplete LD with other 17q21 variants. The CTCF-switching effect requires rs12936231 and rs4065275 acting together. The independent GWAS-significant asthma signal carried by rs2305480 (GSDMB missense p.Pro311Ser) and rs8076131 are in the same haploblock but can be partly separated statistically, meaning carriers of rs12936231 CC who also carry rs2305480 GG have an additive airway risk via two distinct mechanisms (regulatory ORMDL3 overexpression plus increased GSDMB pyroptotic activity). The IKZF3 variant rs2872507 at the same locus has a distinct pleiotropic profile — GG is asthma-risk but AA is autoimmune-risk — creating complex genotype combinations worth tracking in multi-condition risk assessments.